Abstract
Over the last few years, consistent data have demonstrated that creatine (Cr) supplementation prevents the accumulation of fat in rat liver as well as the progression of fatty liver disease in different situations. Studies have demonstrated that Cr is effective and prevents fatty liver in high-fat and choline-deficient diets and in hepatoma cells in vitro. Because Cr synthesis is responsible for a considerable consumption of hepatic methyl groups, studies have tested the idea that Cr supplementation could modulate phospholipid formation and VLDL secretion. Studies have also demonstrated Cr is able to modulate the expression of key genes related to fatty acid oxidation in hepatocyte cell culture and in rat liver. However, to date, the mechanism by which Cr exerts protective effects against fatty liver is poorly understood. Therefore, the present review aims to summarize the studies involving the therapeutic use of Cr supplementation on fatty liver disease and to explore the mechanisms involved in one-carbon and fatty acid metabolism for the preventive effects of Cr supplementation on fat liver accumulation. Although a small number of studies have been conducted to date, we consider Cr as a new and promising therapeutic strategy to control fat accumulation in the liver as well as the progression of fatty liver disease.
Similar content being viewed by others
Abbreviations
- AMPK:
-
AMP-activated protein kinase
- BHMT:
-
Betaine-homocysteine S-methyltransferase
- CK:
-
Creatine kinase
- DNL:
-
De novo lipogenesis
- McA:
-
McArdle
- NAFLD:
-
Non-alcoholic fatty liver disease
- NASH:
-
Non-alcoholic steatohepatitis
- NEFA:
-
Non-esterified fatty acids
- PE, PEMT:
-
Phosphatidylethanolamine N-methyltranferase
- PL:
-
Phosphatidylcholine
- SAH:
-
S-adenosylhomocysteine
- SAM:
-
S-adenosylmethionine
- TAG:
-
Triacylglycerols
References
Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ (2011) PPARα expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 141(4):603–610. doi:10.3945/jn.110.135210
Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM (2013) PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 19(5):557–566. doi:10.1038/nm.3159
Al Rajabi A, Castro GS, da Silva RP, Nelson RC, Thiesen A, Vannucchi H, Vine DF, Proctor SD, Field CJ, Curtis JM, Jacobs RL (2014) Choline supplementation protects against liver damage by normalizing cholesterol metabolism in Pemt/Ldlr knockout mice fed a high-fat diet. J Nutr 144(3):252–257. doi:10.3945/jn.113.185389
Alves CR, Ferreira JC, de Siqueira-Filho MA, Carvalho CR, Lancha AH Jr, Gualano B (2012) Creatine-induced glucose uptake in type 2 diabetes: a role for AMPK-alpha? Amino Acids 43(4):1803–1807. doi:10.1007/s00726-012-1246-6
Bessman SP, Carpenter CL (1985) The creatine-creatine phosphate energy shuttle. Annu Rev Biochem 54:831–862. doi:10.1146/annurev.bi.54.070185.004151
Brosnan JT, Brosnan ME (2007) Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annu Rev Nutr 27:241–261. doi:10.1146/annurev.nutr.27.061406.093621
Brosnan JT, da Silva RP, Brosnan ME (2011) The metabolic burden of creatine synthesis. Amino Acids 40(5):1325–1331. doi:10.1007/s00726-011-0853-y
Caballero F, Fernandez A, Matias N, Martinez L, Fucho R, Elena M, Caballeria J, Morales A, Fernandez-Checa JC, Garcia-Ruiz C (2010) Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-l-methionine and glutathione. J Biol Chem 285(24):18528–18536. doi:10.1074/jbc.M109.099333
Ceddia RB, Sweeney G (2004) Creatine supplementation increases glucose oxidation and AMPK phosphorylation and reduces lactate production in L6 rat skeletal muscle cells. J Physiol 555:409–421. doi:10.1113/jphysiol.2003.056291
Choe CU, Nabuurs C, Stockebrand MC, Neu A, Nunes P, Morellini F, Sauter K, Schillemeit S, Hermans-Borgmeyer I, Marescau B, Heerschap A, Isbrandt D (2013) L-arginine:glycine amidinotransferase deficiency protects from metabolic syndrome. Hum Mol Genet 22(1):110–123. doi:10.1093/hmg/dds407
da Silva RP, Nissim I, Brosnan ME, Brosnan JT (2009) Creatine synthesis: hepatic metabolism of guanidinoacetate and creatine in the rat in vitro and in vivo. Am J Physiol Endocrinol Metab 296(2):E256–E261. doi:10.1152/ajpendo.90547.2008
da Silva RP, Kelly KB, Leonard KA, Jacobs RL (2014) Creatine reduces hepatic TG accumulation in hepatocytes by stimulating fatty acid oxidation. Biochim Biophys Acta 1841 11:1639–1646. doi:10.1016/j.bbalip.2014.09.001
Day CP, James OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114(4):842–845
Deminice R, Portari GV, Vannucchi H, Jordao AA (2009) Effects of creatine supplementation on homocysteine levels and lipid peroxidation in rats. Br J Nutr 102(1):110–116. doi:10.1017/S0007114508162985
Deminice R, da Silva RP, Lamarre SG, Brown C, Furey GN, McCarter SA, Jordao AA, Kelly KB, King-Jones K, Jacobs RL, Brosnan ME, Brosnan JT (2011) Creatine supplementation prevents the accumulation of fat in the livers of rats fed a high-fat diet. J Nutr 141(10):1799–1804. doi:10.3945/jn.111.144857
Deminice R, da Silva RP, Lamarre SG, Kelly KB, Jacobs RL, Brosnan ME, Brosnan JT (2015a) Betaine supplementation prevents fatty liver induced by a high-fat diet: effects on one-carbon metabolism. Amino Acids 47(4):839–846. doi:10.1007/s00726-014-1913-x
Deminice R, de Castro GS, Francisco LV, da Silva LE, Cardoso JF, Frajacomo FT, Teodoro BG, Dos Reis Silveira L, Jordao AA (2015b) Creatine supplementation prevents fatty liver in rats fed choline-deficient diet: a burden of one-carbon and fatty acid metabolism. J Nutr Biochem 26(4):391–397. doi:10.1016/j.jnutbio.2014.11.014
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Investig 115(5):1343–1351. doi:10.1172/JCI23621
Earnest CP, Almada AL, Mitchell TL (1996) High-performance capillary electrophoresis-pure creatine monohydrate reduces blood lipids in men and women. Clin Sci 91(1):113–118
Edison EE, Brosnan ME, Meyer C, Brosnan JT (2007) Creatine synthesis: production of guanidinoacetate by the rat and human kidney in vivo. Am J Physiol Renal Physiol 293(6):F1799–F1804. doi:10.1152/ajprenal.00356.2007
Gao Q, Jia Y, Yang G, Zhang X, Boddu PC, Petersen B, Narsingam S, Zhu YJ, Thimmapaya B, Kanwar YS, Reddy JK (2015) PPARα-deficient ob/ob obese mice become more obese and manifest severe hepatic steatosis due to decreased fatty acid oxidation. Am J Pathol 185(5):1396–1408. doi:10.1016/j.ajpath.2015.01.018
Garcia-Ruiz C, Baulies A, Mari M, Garcia-Roves PM, Fernandez-Checa JC (2013) Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: cause or consequence? Free Radical Res 47(11):854–868. doi:10.3109/10715762.2013.830717
Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278(36):34268–34276. doi:10.1074/jbc.M300043200
Gawrieh S, Chalasani N (2015) Pharmacotherapy for nonalcoholic fatty liver disease. Semin Liver Dis 35(3):338–348. doi:10.1055/s-0035-1562951
Ghoshal AK, Ahluwalia M, Farber E (1983) The rapid induction of liver cell death in rats fed a choline-deficient methionine-low diet. Am J Pathol 113(3):309–314
Gualano B, Artioli GG, Poortmans JR, Lancha Junior AH (2010) Exploring the therapeutic role of creatine supplementation. Amino Acids 38(1):31–44. doi:10.1007/s00726-009-0263-6
Gualano B, Pinto AL, Perondi MB, Roschel H, Sallum AM, Hayashi AP, Solis MY, Silva CA (2011) Therapeutic effects of exercise training in patients with pediatric rheumatic diseases. Revista Brasileira de Reumatologia 51(5):490–496
Hardy T, Anstee QM, Day CP (2015) Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol 31(3):175–183. doi:10.1097/MOG.0000000000000175
Harris RC, Soderlund K, Hultman E (1992) Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci 83(3):367–374
Jacobs RL, Lingrell S, Zhao Y, Francis GA, Vance DE (2008) Hepatic CTP:phosphocholine cytidylyltransferase-alpha is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. J Biol Chem 283(4):2147–2155. doi:10.1074/jbc.M706628200
Jacobs RL, Zhao Y, Koonen DP, Sletten T, Su B, Lingrell S, Cao G, Peake DA, Kuo MS, Proctor SD, Kennedy BP, Dyck JR, Vance DE (2010) Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity. J Biol Chem 285(29):22403–22413. doi:10.1074/jbc.M110.108514
Jay MA, Ren J (2007) Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabet Rev 3(1):33–39
Johnson NA, George J (2010) Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 52(1):370–381. doi:10.1002/hep.23711
Kawano Y, Cohen DE (2013) Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 48(4):434–441. doi:10.1007/s00535-013-0758-5
Kazak L, Chouchani ET, Jedrychowski MP, Erickson BK, Shinoda K, Cohen P, Vetrivelan R, Lu GZ, Laznik-Bogoslavski D, Hasenfuss SC, Kajimura S, Gygi SP, Spiegelman BM (2015) A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell 22(3):643–655. doi:10.1016/j.cell.2015.09.035
Kharbanda KK, Mailliard ME, Baldwin CR, Beckenhauer HC, Sorrell MF, Tuma DJ (2007) Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol 46(2):314–321. doi:10.1016/j.jhep.2006.08.024
Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, Petersen KF, Samuel VT, Shulman GI (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 108(39):16381–16385. doi:10.1073/pnas.1113359108
Kwon do Y, Jung YS, Kim SJ, Park HK, Park JH, Kim YC (2009) Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J Nutr 139(1):63–68. doi:10.3945/jn.108.094771
Larson-Meyer DE, Heilbronn LK, Redman LM, Newcomer BR, Frisard MI, Anton S, Smith SR, Alfonso A, Ravussin E (2006) Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabet Care 29(6):1337–1344. doi:10.2337/dc05-2565
Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, Nonalcoholic Steatohepatitis Clinical Research N (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. Jama 305(16):1659–1668. doi:10.1001/jama.2011.520
Lewis GF, Carpentier A, Adeli K, Giacca A (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23(2):201–229. doi:10.1210/edrv.23.2.0461
Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE (2006) The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 3(5):321–331. doi:10.1016/j.cmet.2006.03.007
Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML, Gonzalez FJ (2003) Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Investig 111(5):737–747. doi:10.1172/JCI17223
Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37(4):909–916. doi:10.1053/jhep.2003.50132
Musso G, Gambino R, Cassader M, Pagano G (2010) A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52(1):79–104. doi:10.1002/hep.23623
Noureddin M, Mato JM, Lu SC (2015) Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med 240(6):809–820. doi:10.1177/1535370215579161
Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F (2015) The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 47(1):4–11. doi:10.1016/j.dld.2014.07.170
Pontikos M, Lu QL, Morgan JE, Hardie DG, Partridge TA, Carling D (1998) Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle. EMBO J 17:1688–1699
Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Investig 118(3):829–838. doi:10.1172/JCI34275
Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, Nash CRN (2010) The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52(3):894–903. doi:10.1002/hep.23759
Schwenger KJ, Allard JP (2014) Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol WJG 20(7):1712–1723. doi:10.3748/wjg.v20.i7.1712
Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, Moyses HE, Calder PC, Byrne CD, On behalf of the WSI (2014) Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the *WELCOME study. Hepatology. doi:10.1002/hep.27289
Selhub J (2002) Folate, vitamin B12 and vitamin B6 and one carbon metabolism. J Nutr Health Aging 6(1):39–42
Song J, da Costa KA, Fischer LM, Kohlmeier M, Kwock L, Wang S, Zeisel SH (2005) Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J Off Publ Fed Am Soc Exp Biol 19(10):1266–1271. doi:10.1096/fj.04-3580com
Stead LM, Au KP, Jacobs RL, Brosnan ME, Brosnan JT (2001) Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab 281(5):E1095–E1100
Stead LM, Brosnan JT, Brosnan ME, Vance DE, Jacobs RL (2006) Is it time to reevaluate methyl balance in humans? Am J Clin Nutr 83(1):5–10
Stockebrand M, Sauter K, Neu A, Isbrandt D, Choe CU (2013) Differential regulation of AMPK activation in leptin- and creatine-deficient mice. FASEB J Off Publ Fed Am Soc Exp Biol 27(10):4147–4156. doi:10.1096/fj.12-225136
Tailleux A, Wouters K, Staels B (2012) Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 1821 5:809–818. doi:10.1016/j.bbalip.2011.10.016
Takasawa K, Kubota N, Terauchi Y, Kadowaki T (2008) Impact of increased PPARγ activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment. Endocr J 55(4):767–776
Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5):1836–1846. doi:10.1002/hep.24001
Vance DE (2013) Physiological roles of phosphatidylethanolamine N-methyltransferase. Biochim Biophys Acta 1831(3):626–632. doi:10.1016/j.bbalip.2012.07.017
Viollet B, Guigas B, Leclerc J, Hébrard S, Lantier L, Mounier R, Andreelli F, Foretz M (2009) AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 196(1):81–98. doi:10.1111/j.1748-1716.2009.01970.x
Vos MB, Lavine JE (2013) Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57(6):2525–2531. doi:10.1002/hep.26299
Wallimann T, Tokarska-Schlattner M, Schlattner U (2011) The creatine kinase system and pleiotropic effects of creatine. Amino Acids 40(5):1271–1296. doi:10.1007/s00726-011-0877-3
Wyss M, Kaddurah-Daouk R (2000) Creatine and creatinine metabolism. Physiol Rev 80(3):1107–1213
Zhang Y, Cui Y, Wang XL, Shang X, Qi ZG, Xue J, Zhao X, Deng M, Xie ML (2015) PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats. Cytokine 75(1):127–135. doi:10.1016/j.cyto.2015.05.031
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108(8):1167–1174
Acknowledgments
Deminice R is suported by Brazilian Grant from Coordenação de Aperfeiçoamento de Pessoal do Ensino Superior (Capes: 88881.068035/2014-01); de Castro GS is supported by Science without Borders Program—Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (246567/2013-9). Brosnan JT and Brosnan ME are supported by grant #97851 from the Canadian Institutes for Health Research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declared that there is no potential conflict of interests regarding this article. Authors declare that this manuscript is a review and did not involve any humans and/or animal research.
Additional information
Handling Editor: T. Wallimann and R. Harris.
Rights and permissions
About this article
Cite this article
Deminice, R., de Castro, G.S., Brosnan, M.E. et al. Creatine supplementation as a possible new therapeutic approach for fatty liver disease: early findings. Amino Acids 48, 1983–1991 (2016). https://doi.org/10.1007/s00726-016-2183-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-016-2183-6